LY4065967

Phase 2Small molecule

LY4065967 is one of 84 small molecule programs targeting Diabetic Peripheral Neuropathic Pain. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic Peripheral Neuropathic PainRecruiting

Osteoarthritis, KneeRecruiting

Chronic PainRecruiting

Diabetic Peripheral Neuropathic PainPhase 2

Recruiting

Osteoarthritis, KneePhase 2

Recruiting

Chronic PainPhase 2

Recruiting

Competition

Competitive Landscape

77 competitors in Chronic Pain

#DrugCompanyPhaseTrials

Voltaren

Novartis

Approved

1 2

Elavil

AstraZeneca

Approved

1 3

Marinol

Jazz Pharmaceuticals

Approved

—4

MS Contin

HHikma Pharmaceuticals LLC

Approved

4 5

Suboxone

IIndivior Inc.

Approved

3 6

Intuniv

PPromius Pharma, LLC

Approved

2 7

Pitocin

RRetrophin

Approved

1 8

Sufenta

LLeaf Vertical Inc.

Approved

1 9

Norpramin

VValidus Pharmaceuticals

Approved

1 10

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Osteoarthritis, Knee

NCT07641517

Phase 2Recruiting

Chronic Pain

NCT07641504

Q3 2027

Phase 2Recruiting

Diabetic Peripheral Neuropathic Pain

NCT07285018

Clinical

Trials by Indication[1]

ART2 trials

A Study of [14C]-LY4065967 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT07039045·16 enrolled

A Study of LY4065967 in Healthy Japanese Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT06594159·59 enrolled

Osteoarthritis, Knee1 trial

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Osteoarthritis

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07641517·150 enrolled

Chronic pain1 trial

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Chronic Low Back Pain

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07641504·150 enrolled

Diabetic Peripheral Neuropathic Pain1 trial

Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY4065967 for the Treatment of Diabetic Peripheral Neuropathic Pain

Recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT07285018·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for LY4065967. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LY4065967 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LY4065967. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Eli Lilly

LY4065967

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2027

Trials by Indication[1]

ART2 trials

Osteoarthritis, Knee1 trial

Chronic pain1 trial

Diabetic Peripheral Neuropathic Pain1 trial

References

Drug Info

Quick Facts

Related News